Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × dabrafenib × Tumor-Agnostic × Clear all

Phase

Status

Completed 8 Recruiting 2 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 15 CNS 4 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Classical hematology 1 Breast 1

Conditions

Interventions

Gemcitabine 13 pembrolizumab 10 Capecitabine 9 Irinotecan 8 Erlotinib Hydrochloride 8 Carboplatin 8 Blood Specimen Collection 7 Paclitaxel 6 Nivolumab 6 Everolimus 6 Docetaxel 6 Cisplatin 6 Cetuximab 6 130-nm albumin-bound paclitaxel 6 vadimezan 5 Fluorouracil 5 Cyclophosphamide 5 trametinib 4 Leucovorin 4 Lapatinib 4 Bevacizumab 4 Albumin-Bound Paclitaxel 4 temsirolimus 3 atezolizumab 3 abemaciclib 3 Trastuzumab 3 Radiation 3 Pemetrexed 3 Methods 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡